{"result": "(\"entity\"<|>ADRENOLEUCODISTROFIA<|>EVENT<|>Adrenoleucodistrofia is a genetic disorder affecting lipid metabolism, characterized by the accumulation of very long-chain fatty acids and leading to neurological symptoms.)\n##\n(\"entity\"<|>ACEITE DE LORENZO<|>ORGANIZATION<|>Aceite de Lorenzo is a dietary supplement used in the treatment of Adrenoleucodistrofia, consisting of a mixture of glycerol trioleate and glycerol trierucate.)\n##\n(\"entity\"<|>BIBLIOGRAFÍA<|>ORGANIZATION<|>Bibliografía refers to the collection of references and studies related to Adrenoleucodistrofia and its treatment.)\n##\n(\"entity\"<|>VAN GEEL BM<|>PERSON<|>Van Geel BM is an author of a study on X-linked adrenoleukodystrophy, focusing on clinical presentation, diagnosis, and therapy.)\n##\n(\"entity\"<|>GIRÓS M<|>PERSON<|>Girós M is an author involved in the protocol for diagnosis, treatment, and follow-up of X-linked adrenoleukodystrophy.)\n##\n(\"entity\"<|>MOSER HW<|>PERSON<|>Moser HW is a researcher known for his work on dietary management and clinical aspects of adrenoleukodystrophy.)\n##\n(\"entity\"<|>POWERS JM<|>PERSON<|>Powers JM is a researcher who has published works on the clinical and therapeutic aspects of adrenoleukodystrophy.)\n##\n(\"relationship\"<|>ACEITE DE LORENZO<|>ADRENOLEUCODISTROFIA<|>Aceite de Lorenzo is used as a dietary treatment for Adrenoleucodistrofia to normalize plasma concentrations of very long-chain fatty acids.<|>8)\n##\n(\"relationship\"<|>VAN GEEL BM<|>BIBLIOGRAFÍA<|>Van Geel BM's study is included in the bibliographic references related to the clinical presentation and therapy of adrenoleukodystrophy.<|>7)\n##\n(\"relationship\"<|>GIRÓS M<|>BIBLIOGRAFÍA<|>Girós M's protocol for diagnosis and treatment is part of the bibliographic references on adrenoleukodystrophy.<|>7)\n##\n(\"relationship\"<|>MOSER HW<|>BIBLIOGRAFÍA<|>Moser HW's research on dietary management is referenced in the bibliographic section regarding adrenoleukodystrophy.<|>7)\n##\n(\"relationship\"<|>POWERS JM<|>BIBLIOGRAFÍA<|>Powers JM's works on clinical aspects of adrenoleukodystrophy are included in the bibliographic references.<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ridos de cadena larga; TCM: triglicéridos de cadena media.\n---\nTema 20. Trastornos congénitos del metabolismo de los lípidos: Adrenoleucodistrofia... 351\n\nácido docosanoico (C26:0:C22:0). Además, el hallazgo de lesiones en la resonancia magnética cerebral y la presencia de insuficiencia suprarrenal confirman el diagnóstico. En la actualidad se puede realizar el análisis genético de mutaciones del gen de la ALD, y es posible el diagnóstico prenatal.\n\nEl tratamiento de la ALD incluye: tratamiento sintomático, tratamiento esteroideo sustitutivo, y una serie de tratamientos que incluyen el abordaje dietético.\n\nEl tratamiento dietético consiste en la restricción de la ingesta de ácidos grasos de cadena muy larga, combinado con la suplementación oral de aceite de Lorenzo (mezcla de gliceril trioleato y gliceriltrierucato en proporción 4:1), que consigue normalizar las concentraciones plasmáticas de ácidos grasos de cadena muy larga. Los resultados clínicos no apoyan el uso de aceite de Lorenzo en pacientes con síntomas neurológicos preexistentes. No obstante, algunos estudios sugieren que la combinación GTO-GTE puede enlentecer el deterioro neurológico de pacientes asintomáticos.\n\nLos intentos de modificar la respuesta inflamatoria cerebral utilizando agentes antiinflamatorios o inmunosupresores no han demostrado eficacia. Se ha utilizado el trasplante de médula ósea en pacientes con afectación neurológica moderada y donante compatible, con resultados reservados debido al alto riesgo del trasplante.\n\nLos trastornos de la β-oxidación de los ácidos grasos son metabolopatías que se heredan de forma autosómica recesiva, y que en su mayor parte se caracterizan por hipoglucemia no cetósica, con mala tolerancia a los períodos de ayuno. Otros síntomas que pueden acompañar a estos trastornos metabólicos son miopatía, hepatopatía, y en ocasiones neuropatía y arritmias cardíacas. El tratamiento dietético juega un papel muy importante en estos trastornos, y está dirigido a evitar los períodos de ayuno y asegurar el aporte de hidratos de carbono de absorción lenta, a la vez que se restringe cuantitativa y cualitativamente las grasas de la dieta.\n\nHay dos tipos fundamentales de trastornos de la β-oxidación de los ácidos grasos: los que afectan a los ácidos grasos de cadena larga y muy larga, y los que afectan a ácidos grasos de cadena media. En el primer caso, debe garantizarse el aporte de ácidos grasos esenciales, y debe suplementarse la dieta con ácidos grasos de cadena media. En el déficit de β-oxidación de los ácidos grasos de cadena media, la restricción cualitativa y cuantitativa de las grasas es más controvertida, y está contraindicado el uso de triglicéridos de cadena media.\n\n## 4. Bibliografía\n\n1. Van Geel BM, Assies J, Wanders RJA, Barth PG. X-linked adrenoleukodystrophy: clinical presentation, diagnosis and therapy. J Neurol Neurosurg Psychiatry 1997; 63: 4-14.\n\n2. Girós M, Gutiérrez-Solana L, Pedrón C, Coll J, Pineda M, Campistol J et al. Protocolo de diagnóstico, tratamiento y seguimiento de Adrenoleucodistrofia ligada al cromosoma X. Asociación Española para el Estudio de los Errores Congénitos del Metabolismo. En: http://ae3com.eu/protocolos/protocolo6.pdf\n\n3. Moser HW. Dietary management of X-linked adrenoleukodystrophy. Annu Rev Nutr 1995; 15: 379-397.\n\n4. Migeon BR, Moser HW, Moser AB, Axelman J, Sillence D, Norum RA. Adrenoleukodystrophy: evidence for X-linkage, inactivation and selection favouring the mutant allele in heterozygous cells. Proc Natl Acad Sci USA 1981; 78: 5066-5070.\n\n5. Gartner J, Braun A, Holzinger A, Roerig P, Lenard HG, Roscher AA. Clinical and genetic aspects of X-linked adrenoleukodystrophy. Neuropediatrics 1998; 29: 3-13.\n\n6. Moser HW. Clinical and therapeutic aspects of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 1995; 54 (5): 740-745.\n\n7. Powers JM. Adrenoleukodystrophy. Clin Neuropathol 1985; 4: 181-199.\n\n8. Powers JM, Liu Y, Moser A, Moser H. The inflammatory myelinopathy of adrenoleukodystrophy:\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}